Your session is about to expire
← Back to Search
Psychological Treatment for Intrusive Thoughts
N/A
Waitlist Available
Led By Ryan J Jacoby, Ph.D.
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Adults ages 18-60 years old
Be between 18 and 65 years old
Must not have
Current Attention Deficit Hyperactivity Disorder (ADHD) that would interfere with attentional tasks.
Unstable dose of psychotropic medications or recent discontinuation of psychotropic medication.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from week 0 (baseline) to post-treatment (week 8)
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing whether psychological treatment can help people with repetitive negative thinking who have trouble stopping unwanted thoughts and shifting their attention.
Who is the study for?
This trial is for adults aged 18-60 in Massachusetts with repetitive negative thinking due to OCD, GAD, or MDD. Participants must be fluent in English, right-handed, have internet access and a device with a camera and microphone. They should not be currently receiving psychotherapy or have unstable psychotropic medication use.
What is being tested?
The study tests if psychological treatments can improve attention control among those who struggle to stop unwanted thoughts related to OCD, GAD, and MDD. It compares Emotion Regulation Therapy focused on Attention Regulation (AR-ERT) against Supportive Psychotherapy (SPT).
What are the potential side effects?
As this is a psychological treatment study involving therapy sessions rather than medications, typical drug side effects are not expected. However, discussing emotional topics may cause temporary discomfort.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 18 and 60 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
My ADHD affects my ability to focus on tasks.
Select...
I have not changed or stopped any mental health medications recently.
Select...
I am currently in psychotherapy or plan to start during the study.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from week 0 (baseline) to post-treatment (week 8)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from week 0 (baseline) to post-treatment (week 8)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change from baseline in transdiagnostic repetitive negative thinking at 8 weeks (as measured by the Perseverative Thinking Questionnaire)
Secondary study objectives
Change from baseline in OCD symptom severity at 8 weeks (as measured by the Yale-Brown Obsessive-Compulsive Scale)
Change from baseline in depression symptom severity (as measured by the Structured Interview Guide for the Hamilton Depression Rating Scale)
Change from baseline in functional impairment (as measured by the Work and Social Adjustment Scale)
+4 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Emotion Regulation Therapy - Attention Regulation (AR-ERT)Experimental Treatment1 Intervention
Individuals with repetitive negative thinking receiving Emotion Regulation Therapy - Attention Regulation.
Group II: Supportive Psychotherapy (SPT)Active Control1 Intervention
Individuals with repetitive negative thinking receiving Supportive Psychotherapy.
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
3,022 Previous Clinical Trials
13,317,452 Total Patients Enrolled
193 Trials studying Depression
34,062 Patients Enrolled for Depression
National Institute of Mental Health (NIMH)NIH
2,927 Previous Clinical Trials
2,744,698 Total Patients Enrolled
704 Trials studying Depression
260,975 Patients Enrolled for Depression
Ryan J Jacoby, Ph.D.Principal InvestigatorMassachusetts General Hospital
2 Previous Clinical Trials
144 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- My ADHD affects my ability to focus on tasks.I am seeking treatment mainly because I can't stop worrying or thinking negatively.You have been diagnosed with a severe mental illness like schizophrenia or bipolar disorder in the past.I have not changed or stopped any mental health medications recently.I am currently in psychotherapy or plan to start during the study.I do not have any health issues that would prevent me from participating.You have a problem with drugs or alcohol that could affect your treatment.I can use a computer and do tasks that require quick responses.You have thoughts of harming yourself or someone else and require immediate medical attention.I have tried therapy or meditation for OCD, GAD, or depression.My condition requires medical intervention.I am between 18 and 60 years old.You must be right-handed.You currently reside in Massachusetts.You have a history of head injury or neurological disease, mental retardation, or intellectual disability that would make it difficult for you to take part in the study.
Research Study Groups:
This trial has the following groups:- Group 1: Supportive Psychotherapy (SPT)
- Group 2: Emotion Regulation Therapy - Attention Regulation (AR-ERT)
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Depression Patient Testimony for trial: Trial Name: NCT04225624 — N/A